BR112016024515A2 - proteínas do agonista do receptor trail de cadeia única - Google Patents

proteínas do agonista do receptor trail de cadeia única

Info

Publication number
BR112016024515A2
BR112016024515A2 BR112016024515A BR112016024515A BR112016024515A2 BR 112016024515 A2 BR112016024515 A2 BR 112016024515A2 BR 112016024515 A BR112016024515 A BR 112016024515A BR 112016024515 A BR112016024515 A BR 112016024515A BR 112016024515 A2 BR112016024515 A2 BR 112016024515A2
Authority
BR
Brazil
Prior art keywords
receptor agonist
trail receptor
agonist proteins
trail
chain trail
Prior art date
Application number
BR112016024515A
Other languages
English (en)
Other versions
BR112016024515B1 (pt
Inventor
Gieffers Christian
C Phillips Darren
G Buchanan Fritz
Thiemann Meinolf
Hill Oliver
E Lappe Susan
Original Assignee
Abbvie Inc
Apogenix Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc, Apogenix Ag filed Critical Abbvie Inc
Publication of BR112016024515A2 publication Critical patent/BR112016024515A2/pt
Publication of BR112016024515B1 publication Critical patent/BR112016024515B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)

Abstract

resumo ?proteínas do agonista do receptor trail de cadeia única? proteínas do agonista do receptor trail específicas, ácidos nucleicos que codificam as mesmas e métodos para tratar um sujeito que apresenta uma doença ou transtorno associada a trail são fornecidos neste relatório. as proteínas do agonista do receptor trail fornecidas neste relatório compreendem três domínios trail solúveis e um fragmento fc. as proteínas do agonista do receptor trail são substancialmente não agregadoras e adequadas para aplicações terapêuticas, de diagnóstico e/ou de pesquisa.
BR112016024515-6A 2014-04-23 2015-04-23 Proteínas agonistas do receptor trail BR112016024515B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461983152P 2014-04-23 2014-04-23
US61/983,152 2014-04-23
PCT/US2015/027270 WO2015164588A1 (en) 2014-04-23 2015-04-23 Single-chain trail-receptor agonist proteins

Publications (2)

Publication Number Publication Date
BR112016024515A2 true BR112016024515A2 (pt) 2017-10-10
BR112016024515B1 BR112016024515B1 (pt) 2020-03-31

Family

ID=53055121

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016024515-6A BR112016024515B1 (pt) 2014-04-23 2015-04-23 Proteínas agonistas do receptor trail

Country Status (37)

Country Link
US (4) US9908927B2 (pt)
EP (2) EP3134430B1 (pt)
JP (2) JP6523331B2 (pt)
KR (2) KR20190135546A (pt)
CN (2) CN111718424A (pt)
AR (1) AR100168A1 (pt)
AU (3) AU2015249649B2 (pt)
BR (1) BR112016024515B1 (pt)
CA (2) CA2946402C (pt)
CL (1) CL2016002683A1 (pt)
CR (1) CR20160516A (pt)
CY (1) CY1120281T1 (pt)
DK (1) DK3134430T3 (pt)
DO (1) DOP2016000284A (pt)
EC (1) ECSP16089579A (pt)
ES (1) ES2672368T3 (pt)
HR (1) HRP20180950T1 (pt)
HU (1) HUE038914T2 (pt)
IL (2) IL248244B (pt)
LT (1) LT3134430T (pt)
MA (2) MA45069A (pt)
MX (2) MX2016013858A (pt)
MY (1) MY181986A (pt)
NO (1) NO2776305T3 (pt)
PE (1) PE20170299A1 (pt)
PH (1) PH12016502079B1 (pt)
PL (1) PL3134430T3 (pt)
PT (1) PT3134430T (pt)
RS (1) RS57153B1 (pt)
RU (1) RU2699285C2 (pt)
SG (3) SG10201806465TA (pt)
SI (1) SI3134430T1 (pt)
TR (1) TR201806912T4 (pt)
TW (2) TWI683825B (pt)
UA (1) UA118286C2 (pt)
UY (1) UY36095A (pt)
WO (1) WO2015164588A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017023646A2 (pt) * 2015-05-04 2018-07-17 Apogenix Ag proteínas agonistas de receptor de cd40 de cadeia simples
EP3364995B1 (en) 2015-10-23 2021-08-04 Apogenix AG Single-chain cd27-receptor agonist proteins
WO2017068185A1 (en) * 2015-10-23 2017-04-27 Apogenix Ag Single-chain gitr-receptor agonist proteins
WO2017068180A1 (en) * 2015-10-23 2017-04-27 Apogenix Ag Single-chain light receptor agonist proteins
WO2017102010A1 (en) * 2015-12-17 2017-06-22 Biontech Rna Pharmaceuticals Gmbh Novel cytokine fusion proteins
EP3423480A1 (en) * 2016-03-01 2019-01-09 The Board of Trustees of the University of Illinois L-asparaginase variants and fusion proteins with reduced l-glutaminase activity and enhanced stability
JP2019518713A (ja) * 2016-03-16 2019-07-04 メリマック ファーマシューティカルズ インコーポレーティッド 癌療法のための改変ｔｒａｉｌ
US10501744B2 (en) 2016-05-04 2019-12-10 Indiana University Research And Technology Corporation Presentation of bioactive proteins
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
JP2019517570A (ja) * 2016-06-13 2019-06-24 メリマック ファーマシューティカルズ インコーポレーティッド Ｔｒａｉｌベースの治療剤または細胞死受容体アゴニストを用いて患者を選択および治療する方法
EP3360898A1 (en) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
US11578315B2 (en) 2017-08-11 2023-02-14 The Board Of Trustees Of The University Of Illinois Truncated guinea pig L-asparaginase variants and methods of use
WO2019178433A1 (en) * 2018-03-15 2019-09-19 Abbvie Inc. Abbv-621 in combination with anti-cancer agents for the treatment of pancreatic cancer
WO2019178438A1 (en) * 2018-03-15 2019-09-19 Abbvie Inc. Abbv-621 in combination with anti-cancer agents for the treatment of cancer
EP4149964A2 (en) 2020-05-15 2023-03-22 Apogenix AG Multi-specific immune modulators
CA3217894A1 (en) 2021-05-28 2022-12-01 Gernot Stuhler Recombinant proteinaceous binding molecules
WO2023088876A1 (en) 2021-11-16 2023-05-25 Apogenix Ag Multi-specific immune modulators

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001025277A1 (en) 1999-10-07 2001-04-12 Maxygen Aps Single-chain antagonist polypeptides
DE19963859A1 (de) 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
CA2314199A1 (en) 2000-07-21 2002-01-21 Robert Simoneau C-chip
CZ308214B6 (cs) 2000-12-07 2020-03-04 Eli Lilly And Company GLP-1 fúzní proteiny
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
AU2003234274A1 (en) 2002-04-26 2003-11-10 California Institute Of Technology D1-1 nucleic acids, polypeptides and related methods
DE102004014983A1 (de) 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
US20060188498A1 (en) * 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
DE602006009786D1 (de) 2005-04-15 2009-11-26 Rappaport Family Inst For Res Anwendung von molekülen und verfahren zur behandlung von mit mcp-1/ccr2 assoziierten krankheiten
CA2606102C (en) 2005-04-26 2014-09-30 Medimmune, Inc. Modulation of antibody effector function by hinge domain engineering
EP1894940A1 (en) 2006-08-28 2008-03-05 Apogenix GmbH TNF superfamily fusion proteins
CA2860950C (en) 2007-07-10 2017-08-01 Apogenix Gmbh Tnf superfamily collectin fusion proteins
EP3002299A1 (en) 2008-06-03 2016-04-06 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
WO2010010051A1 (en) * 2008-07-21 2010-01-28 Apogenix Gmbh Tnfsf single chain molecules
JP2012502994A (ja) 2008-09-22 2012-02-02 アムジエン・インコーポレーテツド 治療方法
CN102317314A (zh) * 2008-10-10 2012-01-11 阿纳福公司 结合trail-r1和trail-r2的多肽
US8664366B2 (en) 2009-01-09 2014-03-04 Apogenix Gmbh Fusion proteins forming trimers
AU2010206681A1 (en) * 2009-01-23 2011-09-01 Biogen Idec Ma Inc. Stabilized Fc polypeptides with reduced effector function and methods of use
EP2516458A1 (en) 2009-12-22 2012-10-31 Novartis AG Tetravalent cd47-antibody constant region fusion protein for use in therapy
EP2560684A4 (en) 2010-04-13 2013-11-20 Medimmune Llc FIBRONECTIN TYPE III DOMAIN MULTIMERIC SCAFFOLDS
US9717803B2 (en) * 2011-12-23 2017-08-01 Innate Pharma Enzymatic conjugation of polypeptides
AU2013291982B2 (en) 2012-07-18 2017-01-12 Apogenix Ag Shortened CD95-Fc variants

Also Published As

Publication number Publication date
EP3134430B1 (en) 2018-03-21
NO2776305T3 (pt) 2018-01-27
WO2015164588A1 (en) 2015-10-29
MX2016013858A (es) 2017-08-02
US9908927B2 (en) 2018-03-06
CN106459221B (zh) 2020-09-01
PH12016502079A1 (en) 2016-12-19
PL3134430T3 (pl) 2018-08-31
US20240174731A1 (en) 2024-05-30
CA2946402C (en) 2023-02-28
IL248244B (en) 2020-03-31
AU2018271369B2 (en) 2020-01-02
CN111718424A (zh) 2020-09-29
JP2017513503A (ja) 2017-06-01
TW201620928A (zh) 2016-06-16
PH12016502079B1 (en) 2016-12-19
AU2015249649B2 (en) 2018-10-04
CL2016002683A1 (es) 2017-07-07
CA2946402A1 (en) 2015-10-29
DOP2016000284A (es) 2017-02-15
CR20160516A (es) 2017-05-10
HUE038914T2 (hu) 2018-12-28
UA118286C2 (uk) 2018-12-26
PE20170299A1 (es) 2017-05-06
TW202024123A (zh) 2020-07-01
JP6523331B2 (ja) 2019-05-29
MX2019013587A (es) 2020-01-13
SG10201806465TA (en) 2018-08-30
PT3134430T (pt) 2018-04-20
HRP20180950T1 (hr) 2018-08-10
US20180222962A1 (en) 2018-08-09
JP2019162114A (ja) 2019-09-26
NZ725476A (en) 2023-09-29
CY1120281T1 (el) 2019-07-10
MY181986A (en) 2021-01-18
BR112016024515B1 (pt) 2020-03-31
EP3134430A1 (en) 2017-03-01
DK3134430T3 (en) 2018-05-22
AU2015249649A1 (en) 2016-11-10
US20210040178A1 (en) 2021-02-11
MA39770A (fr) 2015-10-29
IL248244A0 (en) 2016-11-30
ECSP16089579A (es) 2018-05-31
KR20170012257A (ko) 2017-02-02
RU2699285C2 (ru) 2019-09-04
MA45069A (fr) 2019-04-03
SI3134430T1 (en) 2018-05-31
SG11201608767XA (en) 2016-11-29
US20150337027A1 (en) 2015-11-26
TWI747178B (zh) 2021-11-21
KR20190135546A (ko) 2019-12-06
AR100168A1 (es) 2016-09-14
EP3366699A1 (en) 2018-08-29
ES2672368T3 (es) 2018-06-14
RS57153B1 (sr) 2018-07-31
CA3184067A1 (en) 2015-10-29
CN106459221A (zh) 2017-02-22
TWI683825B (zh) 2020-02-01
JP6714751B2 (ja) 2020-06-24
AU2020202247A1 (en) 2020-04-23
TR201806912T4 (tr) 2018-06-21
UY36095A (es) 2015-10-30
KR102079919B1 (ko) 2020-02-24
AU2018271369A1 (en) 2018-12-20
RU2016145608A (ru) 2018-05-28
LT3134430T (lt) 2018-05-10
IL272612A (en) 2020-03-31
SG10202111785VA (en) 2021-12-30
RU2016145608A3 (pt) 2018-12-26

Similar Documents

Publication Publication Date Title
BR112016024515A2 (pt) proteínas do agonista do receptor trail de cadeia única
MX2017014140A (es) Proteinas agonistas receptoras cd40 de cadena simple.
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
CY1121723T1 (el) Συνδυασμος anti-lag-3 αντισωματων και anti-pd-1 αντισωματων για θεραπεια ογκων
BR112017020054A2 (pt) anticorpos para icos
CY1122803T1 (el) Διαδικασιες γραμμης παραγωγης σπορων και χρησεις αυτων
EA201791093A1 (ru) Антитела к cd47, способы и применение
EA201791485A1 (ru) Анти-cd47-антитела и их применения
BR112016018408A2 (pt) moléculas de anticorpo à lag-3 e usos das mesmas
CL2017000278A1 (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
MX2018000948A (es) Proteinas de fusion que se unen a gitir multivalentes y multiespecificas.
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
UY36859A (es) Anticuerpos anti-bcma, moléculas de unión a antígenos biespecíficas que se unen a bcma y cd3, y usos de estas
EA201692539A1 (ru) Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками
PH12016501366A1 (en) Novel anti-baff antibodies
CY1120997T1 (el) Πρωτεϊνες συντηξης uti
MX2016012219A (es) Agonistas de receptor fgf21 y usos del mismo.
WO2016007919A3 (en) Antibody fragments for detecting cancer and methods of use
BR112017004552A2 (pt) composições farmacêuticas
MX2016014726A (es) Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1.
NZ761611A (en) Single-chain trail-receptor agonist proteins
MX2018004228A (es) Anticuerpo que se une especificamente a erbb3 y uso de este.
EA202092450A2 (ru) Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей

Legal Events

Date Code Title Description
B65X Notification of requirement for priority examination of patent application
B65Y Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/04/2015, OBSERVADAS AS CONDICOES LEGAIS.